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Abstract
SARS-CoV-2, a novel coronavirus reached pandemic status by the World Health
Organization in the spring of 2020. As a novel virus, analysis of the early literature on the
clinical manifestations of SARS-CoV-2 is imperative to help guide clinical practice and inform
future research. Early studies about the clinical manifestation of the virus showed a proportion of
hospitalized patients developing renal abnormalities and AKI. This paper analyzed literature
through searching the PubMed database to assess whether renal abnormalities and AKI were
present in hospitalized SARS-CoV-2 patients, how the renal abnormalities manifested
themselves in patients, and the associated treatment and prognosis of those patient who
developed renal abnormalities.
It was found that presence of comorbidities, advancing age, and severity of illness all
correlated with development of AKI. The literature showed the pooled incidence of AKI in
hospitalized patients to be from 0-36.6% and the presence of hematuria, proteinuria, elevated
BUN, and elevated serum creatinine was frequently reported. Continuous renal replacement
therapy is the mainstay of treatment for AKI and there is no research published on treatments for
AKI specific to SARS-CoV-2. Renal abnormalities and AKI were shown to be linked with a
higher mortality rate and increased the risk of in-hospital death by 3.07 to 5.3-fold. These
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findings indicate the need for more research on how to monitor for early renal dysfunction and
what the best timing and treatment interventions are to try to help mitigate the high risk of
mortality associated with hospitalized SARS-CoV-2 patients with renal complications.
Introduction
In December of 2019, a series of pneumonia cases in Wuhan, China sparked an
investigation into the etiology of these unidentified cases. The etiology was found to be a
coronavirus linked to a seafood market in Wuhan, China. This novel coronavirus was labeled
formally as COVID-19 or SARS-CoV-2.1 The virus is transmitted easily via respiratory droplets
when someone sneezes or coughs and possibly through touching hard surfaces.2 Cases began to
rise at an increasing rate and spread across China and the world. As cases spread and the reach of
the virus started to be known, in the spring of 2020 the World Health Organization labeled the
spread of SARS-CoV-2 a global pandemic and a global public health emergency.1 To date there
have been 21.3 million confirmed cases and 767,422 deaths of SARS-CoV-2 worldwide.3 Since
SARS-CoV-2 was an outbreak of a novel coronavirus, there was no clinical data present from
which to risk stratify patients and guide clinical practice.
Clinical manifestations and severity of illness from SARS-CoV-2 vary from
asymptomatic to critically ill. The most commonly reported symptom according to a study of
symptom data from 373,000 patients with confirmed SARS-CoV-2 was cough, reported in 50%
of people. Fever was reported in 43%, myalgia reported in 36%, and headache reported in 34%
of patients included in the study. Other symptoms reported in a lesser proportion include dyspnea
(29%), sore throat (20%), diarrhea (19%), nausea and vomiting (12%), loss of smell or taste
(<10%), abdominal pain (<10%) and rhinorrhea (<10%).4
Based upon previous evidence from the Severe Acute Respiratory Syndrome (SARS)
outbreak in 2003 and Middle East Respiratory Syndrome (MERS) virus outbreak in 2012, it was
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known that coronaviruses infect the host through binding to angiotensin-converting enzyme 2
(ACE-2) receptors in human cells. Studies have shown evidence that point to the novel
coronavirus, SARS-CoV-2, likely using that same ACE-2 receptor as the SARS virus to infect
humans. ACE-2 receptors are found in the lungs and that is one of the main ways that SARSCoV-2 illness manifests itself. There are also ACE-2 receptors on the kidneys, mouth, tongue,
heart, and intestines. Reports of acute kidney injury, cardiac injury, and gastrointestinal upset in
infected patients seem to point to SARS-CoV-2 manifesting itself in those organs, potentially
through their ACE-2 receptors. Whether the virus directly or indirectly causes those sequelae is
not yet clarified.5
The ACE-2 receptor theory paired with early reports of renal dysfunction in hospitalized
patients with SARS-CoV-2 sparked the thought that SARS-CoV-2 may also be affecting the
kidneys.6 These kidney abnormalities and acute kidney injury (AKI) were also reported in an
early study to be a risk factor for mortality.6 As SARS-CoV-2 spreads it is crucial to gain a
greater understanding for how the virus manifests itself in humans so that clinicians can provide
the best, evidence-based care for their patients. For this reason, it is important to answer the
question of: Are SARS-CoV-2 hospitalized patients at risk for AKI and does presence of AKI in
SARS-CoV-2 patients increase the risk of mortality compared to SARS-CoV-2 patients without
AKI?
In the literature cited in this paper, acute kidney injury is defined using Kidney Disease
Improving Global Outcomes (KDIGO) standards. AKI is defined in the KDIGO guidelines as,
any of the following: increase in serum creatinine (SCr) by ≥ 0.3mg/dl within 48 hours or
increase in SCr to ≥ 1.5 times baseline, which is known to or presumed to have occurred within
the prior 7 days, or urine volume <0.5 L/ /
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Kidney abnormalities imply any
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kidney marker out of the normal range including, hematuria, proteinuria, elevated blood urea
nitrogen (BUN), and elevated serum creatinine among others.
This paper will analyze the current data on kidney abnormalities and AKI in SARS-CoV2 hospitalized patients. This analysis will help to determine what populations of patients are
developing kidney abnormalities and AKI, how kidney abnormalities and AKI are manifesting
themselves in patients, examine the current treatment approaches, and provide insight into the
prognosis of hospitalized patients with kidney abnormalities and AKI. From the literature review
a discussion will synthesize the literature in regards to the research question and point to
important areas needing more research and attention to guide clinical practice during this rapidly
evolving pandemic.

Background
Populations of Patients with Kidney Dysfunction During SARS-CoV-2 Hospitalization
The first step to understanding how SARS-CoV-2 affects hospitalized patients is to look
at what kind of patients are developing kidney dysfunction. A study by Cheng et al.6 of 701
SARS-CoV-2 hospitalized patients showed that when patients were divided into two groups, one
with elevated baseline serum creatinine levels upon admission (n=101) and the other with normal
baseline creatinine levels (n=600), the group with elevated baseline creatinine levels upon
admission developed AKI more frequently than the group of patients that had normal baseline
creatinine levels upon admission, the percentages being 11.9% and 4% respectively, pvalue=0.001. The patients who presented with elevated baseline serum creatinine levels were
more likely to be male (72.3% versus 49%, p-value <0.001), have an increased age (p-value
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<0.001), more severe illness upon presentation (52.5% versus 40.7%, p-value=0.026), have at
least one comorbidity (60% versus 39.6%, p-value <0.001), chronic kidney disease (9% versus
0.8%, p-value <0.001), and hypertension (48% versus 30.9%, p-value=0.001).6 The presence of
these factors made patients more likely to be in the group with elevated baseline creatinine
levels. These patients in the group with elevated creatinine levels show what types of patients
were more likely to develop AKI. Since 6 in 10 adult American patients report having at least
one comorbidity,8 this study points to the risk in the American population for large numbers of
patients to fall into the group of patients that have elevated baseline serum creatinine levels and
potentially be at risk for developing AKI.
These results are echoed by the results of this retrospective preprint study by Shi et al.9
that analyzed the data of 101 SARS-CoV-2 non-survivors. The authors found that 79.2% of
patients had at least one comorbidity, 58.4% had hypertension, 22.8% had cardiovascular
disease, and 20.8% of the non-survivor patients had diabetes. Nearly one quarter of the patients,
all non-survivors, had AKI. It is reasonable to conclude that it is likely that the non-survivors
with AKI had at least one comorbidity present since 79.2% of the patients had at least one
comorbidity. This study cannot, however, provide any insight about the presence of
comorbidities for hospitalized patients with AKI or without AKI that did survive.9 To fully
understand what populations develop AKI, it must be understood what the population of people
with AKI that do survive is made up of. The results from Shi et al.9 echoed the results of Cheng
et al.6 that the presence of comorbidities are an important risk factor in predicting AKI and poor
outcomes as well, though the results from Shi et al.9 could not comment on age or severity of
illness trends due to not comparing results to the group that survived.
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While one drawback of the research from Shi et al.9 was that there was no comparison to
patients that survived, this retrospective cohort study by Zhou et al.10 compared hospital data and
outcomes from 191 SARS-CoV-2 confirmed patients from two hospitals from the beginning of
the pandemic to January 31st in Wuhan, China. The authors compared the data from the group
that died compared to the group that had been discharged. Their study results showed that of the
52 non-survivors, the likelihood of having at least one comorbidity was 67% compared to the
survivor group (n=137) at 40%, p-value=0.0010. Comorbidities that were present at significantly
higher rates in the non-survivor group compared to the survivor group included hypertension
48% versus 23% p-value=0.0008, diabetes 31% versus 14% p-value=0.0051, coronary heart
disease 24% versus 1% p-value <0.0001, chronic obstructive lung disease 7% versus 1% pvalue=0.047, and chronic kidney disease 4% versus 0 p-value=0.024. The high rates of
comorbidities in the non-survivor group of patients is important to note because 50% of the
patients in the non-survivors group had AKI while only 1% of patients in the surviving group
had AKI.10 It is likely, because of this, that non-survivors had AKI and a comorbidity. The study
also reported that patients with a higher Sequential Organ Failure Assessment score (SOFA)
correlated with poorer outcomes or higher risk of death. Since the SOFA score calculates the
levels of organ dysfunction, the presence of comorbidities in significant numbers of hospitalized
patients put patients at higher risk for higher SOFA scores.10 A higher SOFA score is thus a risk
factor for AKI because higher SOFA scores correlates with a higher risk of death which also
correlates with the presence of AKI.
In summary of this study, the presence of AKI in a patient was highly correlated with not
surviving and the patients that were much more likely to be in the non-survivor group were
patients with comorbidities.10 This would make a clinician be able to make the connection that
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the presence of comorbidities in patients make the presence of AKI more likely. While Cheng et
a.
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research shared similar characteristics of being more likely to have AKI, have

comorbidities and be an older age. This makes sense because the elevated creatinine level group
was more likely to have in-hospital death than the normal serum creatinine level group. Thus,
those with advanced age and comorbidities are the people that are more likely to have AKI.
Another characteristic of what the population of people who develop AKI may have was
shown by a retrospective study by Hirsch et al.11 of 5,449 patients in 13 New York City area
hospitals from March 1 to April 5. The authors found that AKI developed most commonly in
those patients with respiratory failure. Of patients on ventilators, 89.7% of patients developed
AKI. Conversely, only 21.7% of patients developed AKI who were not on ventilators. 52.2% of
patients developed AKI within 24 hours of being put on a ventilator. This study found the risk
factors for developing AKI to be older age, those with diabetes or cardiovascular disease, black
race, hypertension, vasopressor use, and need of ventilator. In conclusion the study showed that
multiple risk factors may help to predict the likelihood of AKI development and that the
development of AKI correlates with need for ventilator respiratory support.11 Hirsch et al.
emphasized the correlation between ventilator support and AKI,11 which Cheng et al.6, Zhou et
al.10, and Shi et al.9 did not do, but the risk factors of older age, diabetes, cardiovascular disease,
and hypertension were found by the previous three studies which was also found by Hirsch et
al.11 in New York City. This data from New York City is easier to extrapolate to other urban
populations in the United States than the data from China due to the rates of comorbid conditions
and epidemiological makeup varying so much from country to country. This data from New
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York City supports what the other studies found on the risk factors for developing AKI, the
presence of older age and comorbidities.6, 9-11
To summarize, the literature from Cheng et al.6, Zhou et al.10, Shi et al.9, and Hirsch et
al.11 found a variety of risk factors for developing AKI in hospitalized SARS-CoV-2 patients.
While Cheng et al. emphasized age and severity of disease,6 Hirsch et al emphasized ventilator
support,11 and Zhou et al emphasized SOFA scores correlating with AKI and poor outcomes.10
All four studies, however, agreed that the presence of at least one comorbidity and advanced age
increases the likelihood of AKI development. This was especially true for diabetes, hypertension,
and cardiovascular disease. Clinicians should be aware of these higher risk patients early on,
especially those of older age and those that have the presence of comorbidities, and check
frequently for kidney dysfunction.

Manifestations of Kidney Dysfunction in SARS-CoV-2 Hospitalized Patients
The presence of kidney function abnormalities such as elevated BUN, elevated serum
creatinine, hematuria, and proteinuria are the main kidney abnormalities aside from AKI reported
in the studies reporting on the manifestations of kidney abnormalities in SARS-CoV-2 patients.
AKI is reported as a separate classification than the abnormal kidney markers and classified by
the KDIGO definition of acute kidney injury.7
The prospective cohort study by Cheng et al. found that of the 701 hospitalized SARSCoV-2 patients included in the study, 5.1% of these patients presented with or developed AKI
over the course of hospitalization. 43.9% of patients had proteinuria, 26.7% had hematuria,
14.4% of patients had elevated serum creatinine, 13.1% of patients had a glomerular filtration
rate (GFR) of less than 60 (normal ≥60), and 13.1% had an elevated BUN. The authors
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concluded that, not only was AKI present in 5% of patients, but pre-AKI kidney involvement
was high in patients hospitalized with SARS-CoV-2.6
These results were similar to the results in a preprinted version of a study done by Li and
Wu et al.12 193 hospitalized SARS-CoV-2 patients were included in this retrospective
observational study investigating the changes in the kidney function in these patients. Upon
admission, 59% had proteinuria, 44% had hematuria, 14% had an elevated BUN, and 10% had
an increased serum creatinine. Most of these patients did not qualify as having AKI upon
admission and most non-severe patients with kidney abnormalities never ended up developing
AKI. This study included a control group of hospitalized patients with other pneumonia
unrelated to SARS-CoV-2. The results showed that the rate of AKI and abnormal renal markers
is uniquely high in SARS-CoV-2 compared to hospitalization for other pneumonias. The study
concluded that kidney dysfunction is present even in less severe cases of SARS-CoV-2 that do
not progress to AKI.12 The results of the two studies6,12 are strikingly similar with similar rates of
proteinuria, hematuria, and elevated serum creatinine reported. Both studies discussed how many
of these patients with abnormal kidney markers did not progress to AKI and made the point that
there is kidney involvement even before AKI manifests itself. These results, however, leads to
the question of why so many patients develop kidney abnormalities that do not progress to AKI
or severe illness outcomes.
Another study that evaluated abnormal renal markers was a retrospective study at two
hospitals in Wuhan, China by Deng et al. that analyzed hospital lab data from 109 patients that
died during hospitalization and 116 patients that recovered for a total of 225 patients. Serum
creatinine levels in the group that died were significantly higher over the course of
hospitalization than the group that recovered. This was the same trend that was seen in the serum
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creatinine values on the admission day. The average serum creatinine on the day of admission of
the group that died versus the group that recovered was 89 umol/L and 65 umol/L respectively
(normal=60-110 umol/L). Twenty patients of the group that died, 18.3%, had AKI. Zero patients
in the group that recovered had AKI.13 This evidence would point to the increased likelihood of
more severe disease when AKI is present shown by the 18.3% of patients who died had AKI and
no one who recovered had AKI.
Another important takeaway from this study is the correlation between higher serum
creatinine upon admission and the likelihood of developing AKI. Though Deng et al. found that
higher serum creatinine upon admission was correlated with developing AKI, 13 this finding still
would concur with Cheng et al.6 and Li and Wu et al.12 that found that the pre-AKI renal
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because while Deng et al. found that the mildly elevated serum creatinine correlated with AKI
development, it still often did not end up with AKI development.13 Further investigation would
need to be done to understand when mildly abnormal renal markers correlate with likelihood of
AKI development or when the abnormal renal markers just resolve on their own. It is likely
related to the specific population a study is focusing on, whether it is a group of people with poor
outcomes or a whole group of patients hospitalized and renal markers are analyzed independent
of hospital outcome.
The past studies have established that elevated levels of proteinuria, hematuria, BUN, and
serum creatinine all are present in a large proportion of the hospitalized SARS-CoV-2 patient
groups studied.6,12,13 The other main manifestation of kidney dysfunction is development of AKI.
A prospective observational study by Yu et al. of patients, n=226, admitted to 19 hospital
intensive care units in Wuhan, China over a 24 hour period found the percentage of patients to
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develop AKI as 25.2% or 57 patients.14 Another prospective observational cohort study by
Cummings et al. with 1,150 critically ill patients with SARS-CoV-2 admitted between March 2nd
and April 1st at hospitals in New York City reported that 31% of that group developed AKI
during their hospitalization. 87% of the patients had proteinuria.15 A study from Yang et al.
found that 29% (n=15) of 52 critically ill patients developed AKI. This study did not include the
650 other SARS-CoV-2 hospitalized patients.16
These studies are analyzing critically ill patients and the rates of AKI development are
similar. This rate of anywhere from 25.2%-31% critically ill patients developing AKI14-16 cannot,
however, be extrapolated to the rate for all hospitalized patients. Based on the information
presented about who is most likely to develop AKI, those of older age, presence of
comorbidities, and severity of illness,6,9-11 it is likely that critically ill patients have an overall
higher rate of AKI compared to hospitalized patients as a whole. The AKI rate in overall
hospitalized patients must be analyzed separately from critically ill patients only to fully
understand the scope of AKI in hospitalized patients.
One study that may shed light on what the true rate of AKI in hospitalized patients as a
whole in the United States is, is the retrospective cohort study by Hirsch et al. that gathered data
from 5,449 SARS-CoV-2 patients from March 2 to April 1 admitted into 13 New York City
hospitals. Acute kidney injury developed in 36.6% of patients. Of the patients that developed
AKI, the highest proportion, 46.5% of patients, reached stage 1, 22.4% reached stage 2, and
31.1% reached stage 3 AKI.11 The results by Hirsch et al. of 36.6% of patients developing AKI
during hospitalization11 vary a considerable amount with the results found by Wang and Hu et
al.17 They found the incidence of AKI to be 5% out of 138 hospitalized SARS-CoV-2 patients
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(n=36 intensive care unit (ICU), n=102 non-ICU) in Wuhan, China.17 Zhou et al., in the
retrospective cohort study of 191 patients, reported that 15% n=28 developed AKI.10
While these studies are evaluating all hospitalized patients, those with critical status and
those without, further investigation needs to be done to determine why the rates of AKI vary so
much from study to study from 5% to 36.6%.10,11,17 One possible explanation for this when
synthesized with the earlier data that increased age increases the likelihood for AKI,6,9-11 is that
H
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while Wang and Hu et al. reported a median

age of 54 years for patients included in their research.17 In comparing AKI rates, it would also be
important to compare proportion of ICU patients included, proportion of patients with comorbid
conditions, and compare studies with similar sample sizes. Different countries may have
different true rates of AKI in their hospitalized populations and it would be best for clinicians to
look at the AKI rate in populations most similar to the population in the specific area in which
they practice.
Another example showing how varied the AKI rate is reported in hospitalized patients
comes from Wang and Li e a .
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the patients in the study developed acute kidney injury. 15.5% and 4.3% of the patients in the
study had underlying diabetes and chronic kidney disease (CKD) respectively, which when
combined with who often develops AKI, those with comorbidities,6,9-11 this would make one
think that at least a small percentage of the patients in this study would have developed AKI. The
111 patients in the study without CKD did not develop AKI over the course of their
hospitalization and they did not develop any renal abnormalities. 12 patients in the study had
small and insignificant increases in serum creatinine and/or BUN, but those levels returned to
baseline within 48 hours.18
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These findings differ significantly from the previous studies and this is the only study that
was found with no AKI reported in the SARS-CoV-2 hospitalized patients. Of note, CKD
patients that were not yet using intermittent dialysis to treat the CKD were excluded from the
study. The authors hypothesized that this group may be a group that could be susceptible to the
impacts of SARS-CoV-2 on kidney function.18 This study had a median age of 54 years which is
lower than the studies that report higher AKI rates,10,11 which may contribute to the non-existent
AKI rate as well. It is extraordinary that no one developed AKI in this study,18 especially when
Hirsch et al.11 reported that 36.6% of the patients included in that study developed AKI. There
must be something different between the New York City hospitalized population versus the
hospitalized population in Wuhan, China, as the definitions of AKI used in both studies was the
same, the KDIGO definition, and both were analyzing AKI rates in all hospitalized patients.11,18
The extent of the incidence of AKI across all SARS-CoV-2 hospitalized patients is not
yet clear and according to both the prospective and retrospective cohort studies discussed, the
true incidence value may range anywhere from 0-36.6%10,11,17,18. This is likely dependent on
many factors and maybe most importantly the specific hospitalized population being studied. A
meta-analysis of 6 retrospective and 3 prospective cohort studies would support this hypothesis.
The meta-analysis found the pooled incidence of AKI to be 3% in hospitalized patients and 19%
in ICU patients.19 The key to understanding the range in incidence of AKI in SARS-CoV-2
hospitalized patients may be in separating ICU patients versus non-ICU patients and really
understanding the epidemiological data of the patients included in the study including age,
severity of disease, and presence of comorbidities as those have all been shown to be risk factors
for developing AKI.6,9-11 and comparing those proportions to the epidemiological data in local
areas. If one hospital in Wuhan, China has a different median age and fewer comorbidities than
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an older, urban population in New York City with a higher rate of comorbidities, it would make
sense that the AKI rates could be drastically different. Since treating AKI and severely ill
patients utilizes large amounts of resources, understanding the epidemiological makeup of the
population a hospital is serving is important to understand the true incidence of AKI in a
particular geographical area. Further data is needed to find the true rate of AKI in SARS-CoV-2
hospitalized patients, where data from ICU patients and non-ICU patients is separated and other
factors are controlled for.

Treatment of AKI in SARS-CoV-2 Hospitalized Patients
Treatment of patients that develop AKI is multifaceted. Mainstays of treatment that will
be discussed here include continuous renal replacement therapy (CRRT), hemoperfusion,
extracorporeal membrane oxygenation (ECMO), and anticoagulation. The specific types of
CRRT discussed include CVVHD (continuous veno-venous hemodialysis) and CVVHDF
(continuous veno-venous hemodiafiltration). While evidence is limited on outcomes of
treatments specific to SARS-CoV-2, clinical correlations may be able to be found comparing the
data from treatment of AKI in hospitalized patients with infections and those with SARS-CoV-2
specifically.
CRRT is the main treatment for AKI patients as it functions as an external kidney when
the kidneys themselves are failing from the AKI and unable to filter the blood. CRRT reduces
the workload on the kidneys and gives time for the kidneys to heal. The indications for starting
CRRT in AKI patients in general counting those with SARS-CoV-2 include, oliguria with
hypervolemia, hyperkalemia, severe acidosis, and azotemia. There is no research to suggest that
the indications for starting CRRT in SARS-CoV-2 patients should be any different than the
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standard indications for starting CRRT in AKI patients without SARS-CoV-2.20 The methods of
CRRT mentioned above, CVVHD and CVVHDF are both used frequently in AKI patients.
Ronco et al., suggest from clinical experience that CRRT is preferred over intermittent
hemodialysis in hemodynamically unstable critically ill SARS-CoV-2 patients, and specifically
CVVHD or CVVHDF with blood flow over 150mL/min should be used.20 There is no research,
however, to suggest either method of CRRT causes better outcomes than the other in SARSCoV-2 patients. Critically ill SARS-CoV-2 patients have elevated levels of cytokines in the
blood. Though hemofiltration through CVVHDF theoretically may remove cytokines at
increased rates than CVVHD, previous studies in non-SARS-CoV-2 patients found no difference
in outcomes between CVVHDF and CVVHD.2 Thus with the current research, there is no
evidence to suggest either CVVHDF or CVVHD is preferred for SARS-CoV-2 patients.
CRRT is the mainstay of treatment for AKI in critically ill patients. The meta-analysis of
6 retrospective and 3 prospective cohort studies discussed above analyzed the incidence of AKI
and CRRT in SARS-CoV-2 hospitalized patients. In hospitalized patients 2% used CRRT and in
ICU patients, 13% used CRRT.19 Reported percentages of AKI patients requiring CRRT was 317%2 and 14.3%.11 The true proportion of AKI patients that require CRRT will depend on many
factors. Since the values in the research have a large range and since CRRT requires a significant
amount of resource management,2 it is prudent for healthcare systems to plan for how to allocate
potentially scarce CRRT resources for large numbers of patients if the amount of AKI patients
requiring CRRT falls on the higher end of the reported percentages.
Utilizing ECMO in addition to CRRT has shown encouraging outcomes in critically ill
SARS-CoV-2 patients.20 ECMO functions to take over the work of gas exchange in the blood to
decrease the work on over stressed lungs and heart in critically ill patients with respiratory
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failure. While published outcomes on SARS-CoV-2 patients that utilized ECMO are limited, Li
and Guo et al.21 published results on the outcomes of eight SARS-CoV-2 patients that used
ECMO starting during cardiopulmonary resuscitation that could not be stabilized with
mechanical ventilation alone at a hospital in Shanghai, China. When the results were published
four of the eight patients had died. Three of the patients that had survived at the time of
publication were no longer using ECMO, but were still on mechanical ventilation and one patient
had yet to be weaned off the ECMO.21 While these results cannot be extrapolated too
significantly due to such a small sample size and not discussing the rates of concurrent CRRT,
these e
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stabilized on ventilators alone seems promising and should guide future research. Previous
studies of the treatment of acute respiratory distress syndrome (ARDS) and AKI have shown
evidence of safety and efficacy with concurrent CRRT and ECMO treatments,22 which is why
early encouraging results of treating AKI and ARDS SARS-CoV-2 patients with CRRT and
ECMO indicates the immediate need for further clinical trials to see if outcomes are indeed
better with ECMO and CRRT concurrently in these critically ill patients than CRRT alone.
While CRRT is the mainstay of treatment for AKI patients and works as an artificial
kidney, there is also viremia present in some SARS-CoV-2 critically ill patients so the use of
hemoperfusion devices that filter the blood through an external capsule and binds pathogens in
the blood are also being investigated. One of the indications being studied to initiate
hemoperfusion is when multiple organ failure is present. One hemoperfusion device specifically,
the Seraph 100 Microbind Affinity Blood Filter (Seraph 100) from ExThera Medical, has
evidence that it is effective at filtering out pathogens and cytokines from blood and is the only
device that has been approved for that indication.23 The filter has small beads that imitate the
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receptors that pathogens often bind to in human cells. When blood flows through the filter, the
pathogens irreversibly bind to the beads and are filtered from the blood.24 In vitro virus binding
studies from ExThera Medical have shown that the Seraph 100 has potential at filtering out
SARS-CoV-2 and helping in treatment of patients. Historically, in vitro effectiveness has often
translated to in vivo effectiveness with this specific filter.23 Unbiased clinical trials are needed to
see if the claim that the Seraph 100 can help in SARS-CoV-2 treatment is true.
These findings from the Seraph 100 when taken together may point to a promising
method to help severe SARS-CoV-2 patients with viremia and organ failure including AKI.
There is research being performed in SARS-CoV-2 patients in Germany, Italy, and the United
States that is trying to determine if this filter produces superior outcomes compared to not using
hemoperfusion.23 Early results from treatment of critically ill SARS-CoV-2 patients were
encouraging and the FDA granted the Seraph 100 an Emergency Use Authorization (EUA) for
the treatment of SARS-CoV-2.24 There are no published results yet, but if the studies show that
hemoperfusion with the Seraph 100 causes better outcomes, recommendations for its use will be
produced. It makes sense that a device like the Seraph 100 is showing promising results because
it is trying to directly remove virus from the blood, which is the problem causing the AKI in the
first place. Conversely, CRRT is treating the symptom of the AKI which is renal failure and
trying to give the kidneys time to heal on their own, but not trying to help clear the virus so that
the cascade that is leading to AKI can decelerate.
Anticoagulation is another important aspect of therapy to consider in AKI patients that
are being treated with CRRT. Hemofiltration (CVVHDF) can increase coagulopathy risk in
addition to the already hypercoagulable state in these SARS-CoV-2 critically ill patients with
high levels of cytokines. Thus, anticoagulation should be started in patients without
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contraindications to prevent further coagulopathies.2 Klok et al. reported the risk of thrombotic
events (pulmonary embolism, other venous thromboembolic events, and arterial thrombotic
events) to be 31% in ICU patients and the combined adjusted risk of thrombotic events to be
49%.25 Since this percentage is so high, and since patients receiving CRRT are likely to be in the
ICU this means that the risk of thrombotic events in patients receiving CRRT is very high. Thus
prophylactic anticoagulation in these patients being treated for AKI is necessary to attempt to
prevent thrombotic complications.
Research specific to treatments for AKI in SARS-CoV-2 patients are lacking. Further
clinical trials are needed to determine if either CVVHD or CVVHDF result in superior outcomes
for patients. Clinical trials should try to determine if hemoperfusion is helpful for SARS-CoV-2
patients that have organ failure and have viremia. Clinical trials should investigate the
indications and outcomes for concurrent CRRT and ECMO to determine the best timing and use
of ECMO in SARS-CoV-2 patients. While clinical correlations from treatments of other
respiratory infections in the past can help guide treatment of SARS-CoV-2 while there is yet a
void in research specific to this virus, clinical trials are needed so treatment of SARS-CoV-2 can
be tailored to the pathophysiology of this virus to hopefully improve the outcomes for critically
ill patients.

Prognosis of SARS-CoV-2 Patients with Kidney Dysfunction
Previous studies have alluded to an association between AKI and risk of death, but the
literature must be analyzed to determine what the prognosis of patients who develop AKI or
kidney abnormalities while hospitalized with SARS-CoV-2 is. While Cheng et al. presented data
on the population of patients with AKI and the manifestations of AKI, the conclusion of the
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study was to point out the correlation between kidney abnormalities and the associated in
hospital death risk.6 This was the first study to document this association. Using Kaplan Meier
analysis, Cheng et al. found that AKI itself was a risk factor for mortality. Further investigation
showed that elevated BUN or creatinine, presence of proteinuria or hematuria, peak serum
creatinine over 133 umol/L, and AKI greater than or equal to stage 2 were all independent risk
factors for in hospital death even after confounding variables were adjusted for. The study
showed that those with stage 3 AKI had a 4.0 times higher risk of mortality than those patients
without. The authors concluded that kidney abnormalities were risk factors for clinicians to stay
aware of to predict patients that are at a higher risk for in-hospital death so interventions can be
started without hesitation.6
Li and Wu et al., as mentioned previously, studied 163 SARS-CoV-2 patients and found
that the presence of hematuria, proteinuria, and elevated BUN or creatinine were all individually
correlated with disease mortality. A cox regression showed that patients that developed AKI had
a 5.3 times higher mortality rate when compared to patients that did not develop AKI. While
having comorbidities increases one s risk of developing AKI, once one develops AKI, the risk of
death is significantly higher, 5.3 times, than the increased risk of death with the presence a
comorbidity alone, 1.5 times.12 Cheng et al.6 and Li and Wu et al.12 both reported an increased
risk of mortality with the presence of hematuria, proteinuria, elevated BUN or elevated
creatinine. This may be explained by when end organ damage starts to be present in a patient, it
signifies how critically ill the patient is or is on the way to becoming.
Li and Wu et al. reported a 5.3 times higher risk of mortality with AKI,12 Cheng et al.
reported a 4.0 times higher risk of mortality with stage 3 AKI,6 and research done by another
study, by the Korean National Health Insurance Big Data of 9,147 SARS-CoV-2 positive
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patients, showed an odds ratio of death in AKI patients to be 3.07-fold higher.26 These three
values vary from 3.07-5.3 fold,6,12,26 which shows that there is clearly an increased odds of
mortality with AKI present. While the extent of the increased risk requires further investigation
and controls to ensure the populations being compared are the same, it is clear that AKI does
significantly increase the risk of death for SARS-CoV-2 patients, which shows how important it
is to find these patients at risk early and know how to treat them properly.
A study by Yang et al. helps analyze what the increased risk of death for patients with
AKI looks like in numbers. The study included 52 severely ill SARS-CoV-2 patients at a hospital
in Wuhan, China. 20 of those patients in the study recovered and 3 (15%) of those patients had
AKI during their hospital stay. Of the group of 32 that died, 12 of those patients (37.5%) had
AKI during their hospitalization.16 This study showed the rate of AKI to be more than double in
the group that died in the ICU than the group that recovered from the ICU. 32 patients of these
severely ill patients (62.5%) had died at 28 days from admission.16 Based on this data, it was
more likely if a critically ill patient developed AKI that they would die rather than survive.
These results from Yang et al. found a higher rate of AKI in the death group16 compared
to the research by Shi et al. where 101 non-survivor clinical characteristics were analyzed. Shi et
al. found 23.8% of those non-survivors to have AKI.9 This is less than Yang et a
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37.5%.16 The direct comparison of these two percentages is complicated by the fact that the
populations studied were not exactly the same. Shi et al. studied the data from 101 confirmed
deaths9 in comparison to Yang et al, where the 37.5% comes from the percentage of patients with
AKI who died out of a cohort of 52 critically ill patients where some survived.16 These AKI rates
of 23.8%-37.5% cannot be applied to the United States hospitalized AKI rate as a whole as it
was looking at AKI in the proportion of people who died. These percentages only apply to what
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the AKI rate may be in the critically ill patients who do not survive in patients in the areas
studied.
Yang et al.16 and Shi et al.9 looked at the percentage of people with AKI out of a group of
patients that did not survive. This leaves out valuable information when trying to understand
prognosis about how many people with AKI survived and were not counted in that number.
Another way to look at the prognosis of patients with AKI is to look at the mortality rate in the
group of patients that develop AKI. Zhou et al. did that and of those 28 patients that developed
AKI (15% of the study participants), 27 (96%) of them died in the hospital.10 Only one of those
patients with AKI survived. Hirsch et al reported that of those patients that developed AKI, 35%
died, 26% recovered, and 39% were still hospitalized at the time of publication.11 Since 39% of
the patients were still in the hospital, the rates of death in AKI patients across studies cannot be
directly compared. The rate of death in AKI patients in Hirsch et al could be anywhere from 35%
to 74%.11 Either way, the death rate of AKI patients in the two studies vary significantly. When
Hirsch et al.11 a d Z
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10

results are taken together with Yang et al.16 a d S
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results, a clinician can make the connection that AKI may hold a predictive value for death in
hospitalized patients, when anywhere from 29%-37.5%9,16 of patients who died, had AKI and
when 35-74%11 or 96%10 of patients with AKI resulted in death. Further research is needed to
investigate this possible claim, as the rate of death in patients with AKI may be artificially high
in Zhou et al10 and Hirsch et al.11 compared to hospitalized patients in the United States as a
whole.
Chu et al. published a study in 2005 that studied SARS patients clinical data.27 While the
disease in this study is different, the mechanism by which the SARS virus enters cells compared
to SARS-CoV-2 is similar.5 Certain correlations may be able to be found from studying SARS
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patients. In the study of SARS patients, 6.7% of them developed AKI, 91.7% of those patients
that developed AKI died, while only 8.8% of SARS patients without AKI died.27 This difference
is very significant and while it may not be able to directly guide clinical practice due to the
differences in the virus, it can be taken note of that a similar coronavirus had such a devastating
effect on mortality when there was kidney injury present. Zhou et al. reported that 96% of the
patients that developed AKI died10 which is a similar value as found with the SARS patients that
developed AKI, where 91.7% died.27 This may show that SARS and SARS-CoV-2 have similar
effects on the kidney and developing AKI may be highly predictive for mortality for both
conditions. While it was uncommon for SARS patients to develop AKI, it was found to be highly
prognostic for mortality.27
The previous studies presented have shown that AKI correlates with mortality, Wang and
Li et al. as discussed previously, did not find AKI or renal abnormalities in a study of 116
hospitalized SARS-CoV-2 patients. Of the 7 patients that died in the study, none of them had
AKI and none of the 116 patients studied developed AKI at all. One factor to point out was that
CKD patients that were not yet routinely using hemodialysis were excluded from the study.18
T
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why these hospitalized patients were not susceptible to the correlation with mortality that many
of the other studies found is necessary to understand how SARS-CoV-2 causes some patients to
become critically ill and have AKI and some not.
When this data is synthesized elevated BUN, elevated creatinine, proteinuria, hematuria,
and presence of AKI are all individually associated with mortality. Risk of mortality increases
anywhere from 3.07-fold to 5.3-fold when AKI is present. When analyzing the clinical
characteristics of patients that die from SARS-CoV-2, 23.8%-37.5% of them die with AKI.9,16 A
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study by Zhou et al. showed that 96% of the patients with AKI died10 and Hirsch et al found that
35-74% of patients with AKI died.11 When taken together these results seem to show that AKI is
correlated highly and may even be predictive for mortality when hospitalized with SARS-CoV-2.

Methods
To gather the literature to answer the question of the nature of the association between
AKI and SARS-CoV-2, PubMed database and Google Scholar was searched using terms like
COVID , COVID-19 , SARS-CoV-2 , and c

a

. The coronavirus related terms

were searched in combinations with terms that referred to renal abnormalities such as, AKI ,
ac e

d e

, ac e e a fa

e ,

d e
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e a . Review articles citations were

analyzed to find more literature and research that did not readily come up in PubMed searches.
Preprint and early studies were included in this paper due to the emerging nature of the disease
and the need for clinicians to understand the clinical manifestations of SARS-CoV-2 so that
patients can receive the best care possible.

Discussion
This literature analysis was performed to assess the question of if SARS-CoV-2
hospitalized patients are at risk for AKI and does the presence of AKI in SARS-CoV-2 patients
increase the risk of mortality compared to patients without AKI? The literature analysis assessed
what populations are most at risk for developing these kidney abnormalities, evaluated how these
kidney abnormalities and AKI manifest themselves in patients, evaluated if there is any research
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on the effectiveness of treatments for AKI in SARS-CoV-2 patients, and assessed how AKI
changes the prognosis of a hospitalized SARS-CoV-2 patient.
Multiple studies pointed to a trend that underlying comorbid conditions make patients at
higher risk for kidney dysfunction. Frequently mentioned comorbidities included: diabetes,
CKD, hypertension, or cardiovascular disease.6,9-11 The literature also showed that many patients
with abnormal kidney markers or AKI had no underlying renal abnormalities.6,12 With many
patients, even those without comorbidities, developing proteinuria, hematuria, and sometimes
elevated BUN or creatinine, there must be a mechanism that makes patients more susceptible to
kidney complications aside from underlying chronic disease and advancing age which were
frequently cited risk factors for AKI.6,9-11 This could be explained by SARS-CoV-2 binding to
ACE-2 receptors and ACE-2 receptors being present in the kidney.5 Underlying comorbidities,
however, make those patients at highest risk for developing to critically ill status and being
susceptible to poor outcomes.
The literature, other than one study by Wang and Li et al.18 all found that renal
abnormalities and AKI are present in a significant number of SARS-CoV-2 hospitalized patients.
The rate of AKI in ICU patients found in this literature was 25-31%14-16 and the rate reported in
this literature in all hospitalized patients was 0-36.6%.10,11,17,18 Studies also consistently showed a
large proportion of patients presenting with hematuria, proteinuria, elevated serum creatinine and
elevated BUN.6,12 This large range in incidence of AKI in hospitalized patients could be from a
number of factors including the acuity of the majority of the patients included in the study, the
underlying comorbidities in those included, what proportion of patients were included that
ed a d d d
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ere already on RRT or were excluded due to

CKD with pre-RRT status. These differences in data sets could be an explanation for this large
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range of incidences to be present and further investigation is necessary to determine the specific
AKI incidence in hospitalized populations, though the literature shows that it is likely that
increased AKI and kidney abnormalities do exist in SARS-CoV-2 patients. As the pandemic
continues to grow in the United States, this will help hospitals prepare for the potential need to
distribute and monitor use of CRRT in these patients with AKI. The studies, all but one,18 were
unambiguous on the presence of AKI in SARS-CoV-2 hospitalized patients, the question that
remains of exactly how frequently the development of AKI is happening for these hospitalized
patients.
The research was lacking on treatment of AKI specific to SARS-CoV-2 hospitalized
patients. The literature that was included only had general recommendations on the treatment of
these patients. Further research is ongoing and indicated to assess if there is a superior method of
CRRT, either CVVHD or CVVHDF. Currently, there is no evidence to show improved outcomes
with one over the other.20 Hemoperfusion devices are being studied to assess if the
implementation of these devices causes better outcomes in SARS-CoV-2 patients with AKI and
viremia than not using hemoperfusion in conjunction with other therapies.24 The use of ECMO in
conjunction with CRRT is showing promising results and warrants clinical trials to investigate
whether outcomes are improved with ECMO in SARS-CoV-2 patients.21,22 These treatments that
are being investigated for use in conjunction with CRRT, hemoperfusion and ECMO, both can
try to give the patient more time to heal from critical illness and take energy away from things
like oxygenation and the immune system fighting off high levels of virus in the blood. In
addition, strategies with how to deal with cytokine storm in SARS-CoV-2 patients with AKI
needs further research to see if any deviation from standard of care is warranted. According to
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the literature found, treatment of AKI in the setting of SARS-CoV-2 hospitalized patients at this
time follows the same indication and treatment plan as those with sepsis from other infections.20
The prognosis of patients with AKI was also clear throughout the literature. The literature
varied on the extent of the link of AKI with higher mortality and in-hospital death, but all the
literature that reported AKI in patients showed a correlation with death.6,10-12 Not only was AKI
shown to be a significant risk factor for in hospital death, but renal abnormalities of hematuria,
proteinuria, elevated creatinine, and elevated BUN were independent risk factors for in hospital
death as well.6,12 The published literature is clear that there is a significantly higher risk of
mortality in patients with AKI than those without.6,12,26 Research must be done to determine if
this AKI link with mortality is due to correlation with the presence of critical illness or causation
from the SARS-CoV-2 virus itself.
This higher risk of mortality and strong link between AKI and death should be
communicated to clinicians. While there may be no way to prevent kidney abnormalities or AKI
from developing, starting monitoring of kidney markers and urine output early and frequently is
vital for patient outcomes. There is not yet research to prove that early intervention of CRRT can
cause better outcomes in SARS-CoV-2 hospitalized patients, but judicious watchfulness and
early intervention when kidney function starts to become abnormal may help mitigate the
increased risk of mortality that patients with AKI and SARS-CoV-2 have.
One area of further research that may help clinicians be able to act early to help SARSCoV-2 patients that are starting to have kidney complications is the use of FDA approved TIMP2 and IGFBP7 kidney damage urine markers to assess for early kidney damage before standard
kidney markers like urine output and serum creatinine are showing any change.28 Monitoring
these tubal damage markers could be targeted to patients who are high risk for developing AKI,
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for example those with underlying comorbidities.6,9-11 This could potentially help catch the
development of kidney damage earlier and implement interventions earlier. Research is needed
on this topic to determine if outcomes can be improved, but with the significant link of AKI to in
hospital death, it is an important topic to pursue.

Conclusion
The majority of the literature had a consensus that hospitalized SARS-CoV-2 patients are
likely to develop kidney abnormalities and AKI. The studies report differing values and the
range of incidence of AKI is anywhere from 0-36.6%.10,11,17,18 This means that the true value of
the incidence of AKI could be quite small or quite significant. Nonetheless, for those that
develop renal abnormalities or AKI, the literature shows that hematuria, proteinuria, elevated
creatinine, elevated BUN, and presence of AKI are all independent risk factors for in hospital
death even when confounding variables were accounted for.6,10-12,26 This increased risk for in
hospital death was reported as significant frequently.
These findings of the presence of AKI and renal abnormalities and their associated
increased risk of mortality in hospitalized SARS-CoV-2 patients is a significant finding. Patients
that clinicians should be monitoring the most closely are those with underlying comorbidities
such as diabetes, hypertension, cardiovascular disease, advanced age, and severe illness6,9-11 for
changes in urine output and kidney markers such as serum creatinine. Clinicians should monitor
the renal status of these patients frequently and perform interventions early as kidney damage
starts to manifests itself. Future research as to what early kidney damage monitoring methods
work, which treatment interventions are superior, and what the best timing of early treatment is
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for these patients is necessary. This is needed because of the high associated risk of mortality in
patients with the presence of renal abnormalities and AKI and further knowledge on how best to
care for these patients may help to mitigate the risk of de e
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outcome to be death.

References
1. Adapa S, Chenna A, Balla M, et al. COVID-19 pandemic causing acute kidney injury and impact
on patients with chronic kidney disease and renal transplantation. Journal of clinical medicine
research. 2020;12(6):352361. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=7295554&tool=pmcentrez&rendertyp
e=abstract. doi: 10.14740/jocmr4200.
2. Hassanein M, Thomas G, Taliercio J. Management of acute kidney injury in COVID-19. Cleveland
Clinic journal of medicine. 2020. https://www.ncbi.nlm.nih.gov/pubmed/32434806. doi:
10.3949/ccjm.87a.ccc034.
3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
time. The Lancet infectious diseases. 2020;20(5):533534. https://search.datacite.org/works/10.1016/s1473-3099(20)30120-1. doi: 10.1016/s14733099(20)30120-1.
4. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance
united states, january 22 May 30, 2020. MMWR. Morbidity and mortality weekly report.
2020;69(24):759-765. https://search.proquest.com/docview/2415298471. doi:
10.15585/mmwr.mm6924e2.

AKI in SARS-CoV-2 Patients 30
5. Perico L, Benigni A, Remuzzi G. Should COVID-19 concern nephrologists? why and to what
extent? the emerging impasse of angiotensin blockade. Nephron. 2020;144(5):213221. https://www.karger.com/Article/FullText/507305. doi: 10.1159/000507305.
6. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients
with COVID-19. Kidney international. 2020;97(5):829838. https://search.datacite.org/works/10.1016/j.kint.2020.03.005. doi: 10.1016/j.kint.2020.03.005.

7. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO
Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., Suppl. 2012; 2: 1 138.

8. National Center for Chronic Disease Prevention and Health Promotion. Chronic diseases in
america. Centers for Disease Control and Prevention Web
site. https://www.cdc.gov/chronicdisease/resources/infographic/chronic-diseases.htm. Updated
2019. Accessed August 15, 2020.
9. 1. Shi Q, Zhao K, Yu J, et al. Clinical characteristics of 101 COVID-19 nonsurvivors in wuhan,
china: A retrospective study. medRxiv.
2020:2020.03.04.20031039. http://medrxiv.org/content/early/2020/05/20/2020.03.04.20031039.abstr
act. doi: 10.1101/2020.03.04.20031039.
10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with
COVID-19 in wuhan, china: A retrospective cohort study. The Lancet (British edition).
2020;395(10229):1054-1062. https://search.datacite.org/works/10.1016/s0140-6736(20)30566-3.
doi: 10.1016/s0140-6736(20)30566-3.
11. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID19. Kidney international. 2020;98(1):209-218. http://dx.doi.org/10.1016/j.kint.2020.05.006. doi:
10.1016/j.kint.2020.05.006.

AKI in SARS-CoV-2 Patients 31
12. Li Z, Wu M, Yao J, et al. Caution on kidney dysfunctions of COVID-19 patients. SSRN Electronic
Journal. . doi: 10.2139/ssrn.3559601.
13. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus
disease 2019 (COVID-19) in wuhan, china: A retrospective study. Chinese medical journal.
2020;133(11):1261-1267. https://www.ncbi.nlm.nih.gov/pubmed/32209890. doi:
10.1097/CM9.0000000000000824.
14. Yu Y, Xu D, Fu S, et al. Patients with COVID-19 in 19 ICUs in wuhan, china: A cross-sectional
study. Critical care (London, England). 2020;24(1):1219. https://search.proquest.com/docview/2404244253. doi: 10.1186/s13054-020-02939-x.
15. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of
critically ill adults with COVID-19 in new york city: A prospective cohort study. The Lancet (British
edition). 2020;395(10239):1763-1770. http://dx.doi.org/10.1016/S0140-6736(20)31189-2. doi:
10.1016/S0140-6736(20)31189-2.
16. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2
pneumonia in wuhan, china: A single-centered, retrospective, observational study. The lancet
respiratory medicine. 2020;8(5):475-481. https://search.datacite.org/works/10.1016/s22132600(20)30079-5. doi: 10.1016/s2213-2600(20)30079-5.
17. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel
Coronavirus Infected pneumonia in wuhan, china. JAMA : the journal of the American Medical
Association. 2020;323(11):1061-1069. http://dx.doi.org/10.1001/jama.2020.1585. doi:
10.1001/jama.2020.1585.
18. Wang L, Li X, Chen H, et al. Coronavirus disease 19 infection does not result in acute kidney
injury: An analysis of 116 hospitalized patients from wuhan, china. American Journal of Nephrology.
2020;51(5):343-348. https://www.karger.com/Article/FullText/507471. doi: 10.1159/000507471.

AKI in SARS-CoV-2 Patients 32
19. Ng JJ, Luo Y, Phua K, Choong AMTL. Acute kidney injury in hospitalized patients with
coronavirus disease 2019 (COVID-19): A meta-analysis. Journal of Infection.
2020. http://dx.doi.org/10.1016/j.jinf.2020.05.009. doi: 10.1016/j.jinf.2020.05.009.
20. Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID19. The lancet respiratory medicine. 2020;8(7):738-742. http://dx.doi.org/10.1016/S22132600(20)30229-0. doi: 10.1016/S2213-2600(20)30229-0.
21. Li X, Guo Z, Li B, et al. Extracorporeal membrane oxygenation for coronavirus disease 2019 in
shanghai, china. ASAIO Journal. 2020;66(5):475481. https://www.ncbi.nlm.nih.gov/pubmed/32243266. doi: 10.1097/MAT.0000000000001172.
22. Allardet-Servent J, Castanier M, Signouret T, Soundaravelou R, Lepidi A, Seghboyan J. Safety
and efficacy of combined extracorporeal CO2 removal and renal replacement therapy in patients
with acute respiratory distress syndrome and acute kidney injury: The pulmonary and renal support
in acute respiratory distress syndrome study. Critical Care Medicine. 2015;43(12):25702581. https://www.ncbi.nlm.nih.gov/pubmed/26488219. doi: 10.1097/CCM.0000000000001296.
23. Gali Gelman, Mand Van Haa en. E The a

affini

blood fil e i

ed o ea COVID-19

patients. ExThera Medical Web site. http://www.extheramedical.com/newsreleases/2020/3/26/extheras-affinity-blood-filter-is-used-to-treat-covid-19-patients. Updated 2020.
Accessed August 15, 2020.
24. Gali Gelman. US FDA g an

E The a

e a h-100 blood filter emergency use authorization for

the treatment of COVID-19 after promising results in europe and the USA. ExThera Medical Web
site. http://www.extheramedical.com/news-releases/2020/4/17/us-fda-grants-extheras-seraph-100blood-filter-emergency-use-authorization-for-the-treatment-of-covid-19-after-promising-results-ineurope-and-the-usa Web site. . Updated 2020. Accessed August 15, 2020.
25. Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of
thrombotic complications in critically ill ICU patients with COVID-19: An updated

AKI in SARS-CoV-2 Patients 33
analysis. Thrombosis research. 2020;191:148-150. http://dx.doi.org/10.1016/j.thromres.2020.04.041.
doi: 10.1016/j.thromres.2020.04.041.
26. Kim DW, Byeon KH, Kim J, Cho KD, Lee N. The correlation of comorbidities on the mortality in
patients with COVID-19: An observational study based on the korean national health insurance big
data. Journal of Korean medical science.
2020;35(26):e243. https://search.proquest.com/docview/2420633360. doi:
10.3346/jkms.2020.35.e243.
27. Chu KH, Tsang WK, Tang CS, et al. Acute renal impairment in coronavirus-associated severe
acute respiratory syndrome. Kidney International. 2005;67(2):698705. https://search.datacite.org/works/10.1111/j.1523-1755.2005.67130.x. doi: 10.1111/j.15231755.2005.67130.x.
28. Fanelli V, Fiorentino M, Cantaluppi V, et al. Acute kidney injury in SARS-CoV-2 infected
patients. Critical care (London, England). 2020;24(1):1155. https://search.proquest.com/docview/2391273673. doi: 10.1186/s13054-020-02872-z.

Augsburg University Institutional Repository Deposit Agreement
By depositing this Content (“Content”) in the Augsburg University Institutional Repository known as Idun, I agree
that I am solely responsible for any consequences of uploading this Content to Idun and making it publicly available,
and I represent and warrant that:
●

I am either the sole creator or the owner of the copyrights in the Content; or, without obtaining another’s
permission, I have the right to deposit the Content in an archive such as Idun.
● To the extent that any portions of the Content are not my own creation, they are used with the copyright
holder’s expressed permission or as permitted by law. Additionally, the Content does not infringe the
copyrights or other intellectual property rights of another, nor does the Content violate any laws or
another’s right of privacy or publicity.
● The Content contains no restricted, private, confidential, or otherwise protected data or information that
should not be publicly shared.
I understand that Augsburg University will do its best to provide perpetual access to my Content. To support these
efforts, I grant the Board of Regents of Augsburg University, through its library, the following non-exclusive,
perpetual, royalty free, worldwide rights and licenses:
●

To access, reproduce, distribute and publicly display the Content, in whole or in part, to secure, preserve
and make it publicly available
● To make derivative works based upon the Content in order to migrate to other media or formats, or to
preserve its public access.
These terms do not transfer ownership of the copyright(s) in the Content. These terms only grant to Augsburg
University the limited license outlined above.

Initial one:
___ I agree and I wish this Content to be Open Access.
___ I agree, but I wish to restrict access of this Content to the Augsburg University
network.
Work (s) to be deposited

The Presence and Prognosis of Acute Kidney Injury and

Title: _______________________________________________________
Renal Abnormalities in Hospitalized SARS-CoV-2 Patients

Mara Waaraniemi
Author(s) of Work(s): ___________________________________________
Mara Waaraniemi
Depositor’s Name (Please Print): ___________________________________
8/27/20
Author’s Signature: ______________________________ Date: _________
If the Deposit Agreement is executed by the Author’s Representative, the Representative shall separately execute the
Following representation.
I represent that I am authorized by the Author to execute this Deposit Agreement on the behalf of the Author.

Author’s Representative Signature: ___________________ Date: ________

